SCHEMBL22481384

SCHEMBL22481384

CC(C)(C)OC(=O)N[C@@H]1CN(c2nc3ccc(F)cc3[nH]2)CC[C@H]1F

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.45
BACE1 P56817 5/20 0.42
BACE2 Q9Y5Z0 3/20 0.42
HDAC6 Q9UBN7 1/20 0.41
NAMPT P43490 1/20 0.41
PARP1 P09874 1/20 0.41
HRH4 Q9H3N8 2/20 0.39
HRH3 Q9Y5N1 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
MAP4K4 O95819 2/20 0.39
TRPC3 Q13507 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29668194 1.00 LMNA (0.45) LMNABACE1BACE2HDAC6NAMPT
SCHEMBL22550809 0.94 LMNA (0.40) LMNABACE1BACE2HDAC6NAMPT
SCHEMBL22481483 0.91 LMNA (0.45) LMNABACE1BACE2HDAC6NAMPT
SCHEMBL22481386 0.91 LMNA (0.45) LMNABACE1BACE2HDAC6NAMPT
SCHEMBL22481471 0.90 TRPC3 (0.52) LMNABACE1NAMPTHRH4HRH3
SCHEMBL22481580 0.90 NAMPT (0.38) LMNANAMPTPARP1HRH4HRH3
SCHEMBL29668399 0.90 NAMPT (0.38) LMNANAMPTPARP1HRH4HRH3
SCHEMBL22481530 0.90 NAMPT (0.38) LMNANAMPTPARP1HRH4HRH3
SCHEMBL29668183 0.90 NAMPT (0.38) LMNANAMPTPARP1HRH4HRH3
SCHEMBL22481488 0.89 SLC6A9 (0.46) HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220204477-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES TEIJIN PHARMA LIMITED (JP) 2022-06-30 US disclosed
US-11332459-B2 Benzimidazole derivatives and their uses TEIJIN PHARMA LIMITED (JP) 2022-05-17 US disclosed
WO-2020210597-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES AMGEN INC. (US) 2020-10-15 WO disclosed
US-20200308145-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES AMGEN INC. (US) 2020-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200308145-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES TRPC6, TRPV6, TRPM6 LMNA 4022/4885BACE1 4186/4885BACE2 2763/4885
US-20220204477-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES TRPC6, TRPC4, TRPC3 LMNA 2375/4885BACE1 3940/4885BACE2 1946/4885
US-11332459-B2 Benzimidazole derivatives and their uses TRPC6, TRPV6, TRPM6 LMNA 4022/4885BACE1 4186/4885BACE2 2763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.